Sign in

You're signed outSign in or to get full access.

Dina Elmonshed

Vice President in Equity Research at Jefferies Financial Group Inc.

Dina Elmonshed is a Vice President in Equity Research at Jefferies Financial Group, specializing in biotechnology sector analysis with a focus on innovative biotech companies. Her research covers firms such as Moderna and other notable biotech names, delivering market insights and recommendations cited in industry reports, though detailed performance rankings or quantitative metrics are not publicly available. She began her equity research career several years ago, having accumulated three years of experience across two firms prior to joining Jefferies. Elmonshed holds active FINRA registration, is licensed in 53 U.S. states, and maintains a record free of disclosures.

Dina Elmonshed's questions to Moderna (MRNA) leadership

Question · Q1 2025

Dina Elmonshed, on for Michael Yee, asked for Moderna's perspective on a media report suggesting future vaccine trials would require a placebo control and the potential impact on trial enrollment.

Answer

President Stephen Hoge declined to comment on unconfirmed policy changes but noted that many of Moderna's pivotal trials, including for COVID, RSV, CMV, and norovirus, were already placebo-controlled. He emphasized the company's commitment to providing whatever data regulators and public health officials require to support their products.

Ask follow-up questions

Fintool

Fintool can predict Moderna logo MRNA's earnings beat/miss a week before the call